No Data
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $48
H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $44
Promising Potential of Bicara Therapeutics' Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities
Wells Fargo Maintains Bicara Therapeutics(BCAX.US) With Sell Rating, Maintains Target Price $8
Analysts' Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), AstraZeneca (AZN)
Bicara Therapeutics Says Updated Data From Ongoing Phase 1/1b Clinical Trial Of Ficerafusp Alfa In 1L R/M HNSCC To Be Highlighted In Oral Presentation At 2025 ASCO Annual Meeting